Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial.

被引：0

作者：

Berenson, J. R.

Yellin, O.

Bessudo, A.

Boccia, R.

Noga, S.

Gravenor, D.

Patel-Donnelly, D.

Siegel, R. S.

Kewalramani, T.

Gorak, E. J.

Swift, R.

Bensen-Kennedy, D.

机构：

[1] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA

[2] Oncotherapeutics, West Hollywood, CA USA

[3] Pacific Oncol Hematol Associates, Encinitas, CA USA

[4] Ctr Canc & Blood Disorders, Bethesda, MD USA

[5] Weinberg Canc Inst Franklin Sq, Baltimore, MD USA

[6] PLLC, Family Canc Ctr, Memphis, TN USA

[7] Virginia Canc Specialists, Fairfax, VA USA

[8] George Washington Univ, Med Ctr, Washington, DC 20037 USA

[9] Lahey Clin Med Ctr, Burlington, MA 01803 USA

[10] Geisinger Med Ctr, Danville, PA 17822 USA

[11] James R Berenson MD Inc, West Hollywood, CA USA

[12] Cephalon Inc, Frazer, PA USA

来源：

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.8070

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8070

引用

页数：1